---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-112624"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-10-01T13:16:02+00:00"
generated_at: "2026-10-12T14:18:39.922031+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics' rexaceract holds MDS-UPDRS scores stable over 12 months; Phase 2 in Parkinson's set for Q1 2027

## Summary
- 12 of 13 evaluable patients completed the full 12-month rexaceract dosing in the Phase 1b open-label extension; one remaining participant finishes in November 2026.
- MDS-UPDRS Parts II+III motor scores remained stable over 360 days, versus the ~6-point annual increase generally accepted as clinically meaningful PD progression.
- Company expects to submit a new Phase 2 protocol to the FDA in coming weeks and initiate the Phase 2 trial in people with Parkinson's disease in Q1 2027.
- No new safety signals over 12 months; a lower incidence of treatment-emergent adverse events occurred in the nine-month extension (Part 2) than in the initial three-month dosing (Part 1).
- High and low baseline CSF GluSph patients both showed stable motor scores at 12 months; high-baseline patients had large GluSph drops toward healthy levels by day 90 and faster response.

## SEC filing metadata
- accession: 0001104659-26-112624
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-10-01T13:16:02+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926112624/0001104659-26-112624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926112624/tm2626750d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-112624
- JSON: https://secwatch.observer/filing/0001104659-26-112624.json
- Plain text: https://secwatch.observer/filing/0001104659-26-112624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.